PharmaCyte Biotech, Inc. (PMCB) stock
PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
$5.42−0.15 (-2.69%)
Close on Nov 17, 2026Market cap $58.19MP/E –Yield –
PharmaCyte Biotech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
PharmaCyte Biotech's operating income for the twelve months ending Apr 30, 2026 was -$6.85M. For fiscal 2026 it was -$6.85M. The highest annual figure on record is -$1.68M in fiscal 2013.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Apr 30, 2026 | -$6.85M | – |
| FY2025 | Apr 30, 2025 | -$4.38M | – |
| FY2024 | Apr 30, 2024 | -$8.52M | – |
| FY2023 | Apr 30, 2023 | -$6.46M | – |
| FY2022 | Apr 30, 2022 | -$4.39M | – |
| FY2021 | Apr 30, 2021 | -$3.62M | – |
| FY2020 | Apr 30, 2020 | -$3.83M | – |
| FY2019 | Apr 30, 2019 | -$4.10M | – |
| FY2018 | Apr 30, 2018 | -$6.98M | – |
| FY2017 | Apr 30, 2017 | -$4.44M | – |
| FY2016 | Apr 30, 2016 | -$6.07M | – |
| FY2015 | Apr 30, 2015 | -$13.26M | – |
| FY2014 | Apr 30, 2014 | -$18.98M | – |
| FY2013 | Apr 30, 2013 | -$1.68M | – |
| FY2012 | Apr 30, 2012 | -$1.95M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jul 31, 2026 | -$1.01M | – |
| Q4 FY2026CQ1 2026 | Apr 30, 2026 | -$2.51M | – |
| Q3 FY2026CQ4 2025 | Jan 31, 2026 | -$2.12M | – |
| Q4 FY2025CQ1 2025 | Apr 30, 2025 | -$1.04M | – |
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | -$960.25K | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | -$1.11M | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | -$1.27M | – |
| Q4 FY2024CQ1 2024 | Apr 30, 2024 | -$3.17M | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -$1.87M | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -$1.41M | – |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -$2.08M | – |
| Q4 FY2023CQ1 2023 | Apr 30, 2023 | -$903.28K | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -$1.55M | – |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | -$2.32M | – |
| Q1 FY2023CQ2 2022 | Jul 31, 2022 | -$1.68M | – |
| Q4 FY2022CQ1 2022 | Apr 30, 2022 | -$1.51M | – |
| Q3 FY2022CQ4 2021 | Jan 31, 2022 | -$856.12K | – |
| Q2 FY2022CQ3 2021 | Oct 31, 2021 | -$1.00M | – |
| Q1 FY2022CQ2 2021 | Jul 31, 2021 | -$1.02M | – |
| Q4 FY2021CQ1 2021 | Apr 30, 2021 | -$1.03M | – |
| Q3 FY2021CQ4 2020 | Jan 31, 2021 | -$756.85K | – |
| Q2 FY2021CQ3 2020 | Oct 31, 2020 | -$949.52K | – |
| Q1 FY2021CQ2 2020 | Jul 31, 2020 | -$881.68K | – |
| Q4 FY2020CQ1 2020 | Apr 30, 2020 | -$749.89K | – |
| Q3 FY2020CQ4 2019 | Jan 31, 2020 | -$875.31K | – |
| Q2 FY2020CQ3 2019 | Oct 31, 2019 | -$1.07M | – |
| Q1 FY2020CQ2 2019 | Jul 31, 2019 | -$1.13M | – |
| Q4 FY2019CQ1 2019 | Apr 30, 2019 | -$1.17M | – |
| Q3 FY2019CQ4 2018 | Jan 31, 2019 | -$676.35K | – |
| Q2 FY2019CQ3 2018 | Oct 31, 2018 | -$1.04M | – |
| Q1 FY2019CQ2 2018 | Jul 31, 2018 | -$1.22M | – |
| Q4 FY2018CQ1 2018 | Apr 30, 2018 | -$1.45M | – |
| Q3 FY2018CQ4 2017 | Jan 31, 2018 | -$2.03M | – |
| Q2 FY2018CQ3 2017 | Oct 31, 2017 | -$1.81M | – |
| Q1 FY2018CQ2 2017 | Jul 31, 2017 | -$1.69M | – |
| Q4 FY2017CQ1 2017 | Apr 30, 2017 | -$1.15M | – |
| Q3 FY2017CQ4 2016 | Jan 31, 2017 | -$1.28M | – |
| Q2 FY2017CQ3 2016 | Oct 31, 2016 | -$974.20K | – |
| Q1 FY2017CQ2 2016 | Jul 31, 2016 | -$1.03M | – |
See a number that looks wrong?